These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 8654625)

  • 41. Multiple polypoid endometriosis--a rare complication following withdrawal of gonadotrophin releasing hormone (GnRH) agonist for severe endometriosis: a case report.
    Othman NH; Othman MS; Ismail AN; Mohammad NZ; Ismail Z
    Aust N Z J Obstet Gynaecol; 1996 May; 36(2):216-8. PubMed ID: 8798320
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Effects and safety of gonadotrophin-releasing hormone agonist combined with estradiol patch and oral medroxyprogesterone acetate on endometriosis].
    Wang YQ; Zhang SF; Chen X; Zhu J; Hua KQ; Hu WG
    Zhonghua Fu Chan Ke Za Zhi; 2009 Jul; 44(7):504-8. PubMed ID: 19957549
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Medroxyprogesterone acetate supplementation diminishes the hypoestrogenic side effects of gonadotropin-releasing hormone agonist without changing its efficacy in endometriosis.
    Mäkäräinen L; Rönnberg L; Kauppila A
    Fertil Steril; 1996 Jan; 65(1):29-34. PubMed ID: 8557151
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prospective randomized study comparing the GnRH-agonist leuprorelin acetate and the gestagen lynestrenol in the treatment of severe endometriosis.
    Regidor PA; Regidor M; Schmidt M; Ruwe B; Lübben G; Förtig P; Kienle E; Schindler AE
    Gynecol Endocrinol; 2001 Jun; 15(3):202-9. PubMed ID: 11447732
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Reversible bone loss in women treated with GnRH-agonists for endometriosis and uterine leiomyoma.
    Waibel-Treber S; Minne HW; Scharla SH; Bremen T; Ziegler R; Leyendecker G
    Hum Reprod; 1989 May; 4(4):384-8. PubMed ID: 2526152
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Excretion of urinary N-telopeptides reflects changes in bone turnover during ovarian suppression and indicates individually variable estradiol threshold for bone loss.
    Dmowski WP; Rana N; Pepping P; Cain DF; Clay TH
    Fertil Steril; 1996 Dec; 66(6):929-36. PubMed ID: 8941057
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bone densitometry as an adjunct to GnRH agonist therapy.
    Cann CE
    J Reprod Med; 1998 Mar; 43(3 Suppl):321-30. PubMed ID: 9564668
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Testosterone recovery and changes in bone mineral density after stopping long-term luteinizing hormone-releasing hormone analogue therapy in osteoporotic patients with prostate cancer.
    Weston R; Hussain A; George E; Parr NJ
    BJU Int; 2005 Apr; 95(6):776-9. PubMed ID: 15794781
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antiprogestin and/or gonadotropin-releasing hormone agonist for endometriosis treatment and bone maintenance: a 1-year primate study.
    Grow DR; Williams RF; Hsiu JG; Hodgen GD
    J Clin Endocrinol Metab; 1996 May; 81(5):1933-9. PubMed ID: 8626860
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hormonal therapies for endometriosis: implications for bone metabolism.
    Dawood MY
    Acta Obstet Gynecol Scand Suppl; 1994; 159():22-34. PubMed ID: 8209669
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Oral contraceptive pills, gonadotropin-releasing hormone agonists, or use in combination for treatment of hirsutism: a clinical research center study.
    Carr BR; Breslau NA; Givens C; Byrd W; Barnett-Hamm C; Marshburn PB
    J Clin Endocrinol Metab; 1995 Apr; 80(4):1169-78. PubMed ID: 7714086
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of a gonadotropin-releasing hormone agonist on the calcium-parathyroid axis and bone turnover in women with endometriosis.
    Newhall-Perry K; Holloway L; Osburn L; Monroe SE; Heinrichs L; Henzl M; Marcus R
    Am J Obstet Gynecol; 1995 Sep; 173(3 Pt 1):824-9. PubMed ID: 7573251
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Goserelin-induced transient thyrotoxicosis in a hypothyroid woman on L-thyroxine replacement.
    van Bon AC; Wiersinga WM
    Neth J Med; 2008 Jun; 66(6):256-8. PubMed ID: 18689910
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of gonadotropin-releasing hormone agonist on the bone mineral density of patients with endometriosis.
    Uemura T; Mohri J; Osada H; Suzuki N; Katagiri N; Minaguchi H
    Fertil Steril; 1994 Aug; 62(2):246-50. PubMed ID: 8034067
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Randomized clinical trial of a levonorgestrel-releasing intrauterine system and a depot GnRH analogue for the treatment of chronic pelvic pain in women with endometriosis.
    Petta CA; Ferriani RA; Abrao MS; Hassan D; Rosa E Silva JC; Podgaec S; Bahamondes L
    Hum Reprod; 2005 Jul; 20(7):1993-8. PubMed ID: 15790607
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phase II parallel group study showing comparable efficacy between premenopausal metastatic breast cancer patients treated with letrozole plus goserelin and postmenopausal patients treated with letrozole alone as first-line hormone therapy.
    Park IH; Ro J; Lee KS; Kim EA; Kwon Y; Nam BH; Jung SY; Lee S; Kim SW; Kang HS
    J Clin Oncol; 2010 Jun; 28(16):2705-11. PubMed ID: 20421538
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF).
    Fogelman I; Blake GM; Blamey R; Palmer M; Sauerbrei W; Schumacher M; Serin D; Stewart A; Wilpshaar W
    Osteoporos Int; 2003 Dec; 14(12):1001-6. PubMed ID: 14530912
    [TBL] [Abstract][Full Text] [Related]  

  • 58. High bone density in hyperandrogenic women: effect of gonadotropin-releasing hormone agonist alone or in conjunction with estrogen-progestin replacement.
    Simberg N; Tiitinen A; Silfvast A; Viinikka L; Ylikorkala O
    J Clin Endocrinol Metab; 1996 Feb; 81(2):646-51. PubMed ID: 8636283
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of gonadotropin-releasing hormone agonists on bone metabolism markers and bone mineral density in patients with prostate cancer.
    Miyaji Y; Saika T; Yamamoto Y; Kusaka N; Arata R; Ebara S; Nasu Y; Tsushima T; Kumon H
    Urology; 2004 Jul; 64(1):128-31. PubMed ID: 15245949
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bone density in adolescents treated with a GnRH agonist and add-back therapy for endometriosis.
    Divasta AD; Laufer MR; Gordon CM
    J Pediatr Adolesc Gynecol; 2007 Oct; 20(5):293-7. PubMed ID: 17868896
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.